Gratifying new treatment of advanced Urothelial Cancer

Best Practice Nordic | Jun 2019 | ASCO 2019 |

Locally advanced or metastatic urothelial cancer remains a lethal disease with limited treatment options for patients who progress on or after platinum and/or checkpoint inhibitor (CPI).   In this MEDtalk Daniel Peter Petrylak present a new streatment of urothelial cancer  Enfortumab vedotin (EV) - an antibody-drugconjugate targeting Nectin-4, which is highly expressed in UC. This study demonstrate the fact, that Enfortumab vedotin have a therapy that can help people who don’t benefit from checkpoint inhibitors.